Stocks · News reference
Wedbush Reiterates Outperform on Kura Oncology, Maintains $36 Price Target
Wedbush analyst Robert Driscoll reiterates Kura Oncology (NASDAQ:KURA) with a Outperform and maintains $36 price target.
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Jul 28, 2026, 12:55 PM
- Checked
- Jul 28, 2026, 12:55 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Why Cadeler Shares Are Trading Higher By 6%; Here Are 20 Stocks Moving Premarket
Shares of Cadeler A/S (NYSE: CDLR) surged in pre-market trading after reporting strong financial results for the first half of 2026. Revenue and profit increased significantly, and full-year guidance was maintained. Other stocks also moved in pre-market trading.
Read original at benzingaCitizens Reiterates Market Outperform on Kura Oncology, Maintains $24 Price Target
Read original at benzingaDuos Technologies Posts Upbeat Q2 Results, Joins Amylyx Pharmaceuticals, Weave Communications And Other Big Stocks Moving Higher On Tuesday
US stocks down, Nasdaq falls 300+ points. Duos Tech shares rise on better Q2 results. Many other big stocks gain, including Duolingo, Intuit, and Newsmax.
Read original at benzinga